Ageing Research Reviews Impact Factor

For a review journal, the most useful metric here is not the headline JIF alone. It is the combination of a 12.4 two-year JIF and a 14.9 five-year JIF.

That spread matters. It tells you the better ARR papers keep getting used after the first citation wave. In aging research, that usually means reviews that organize a mechanism cleanly, reset how people think about an intervention, or clarify a muddled disease-biology question.

The journal's annual volume also matters. ARR is not trying to publish every competent aging review. It favors reviews that feel field-defining enough to become standard starting points for later work.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 13.35 in 2023 to 13.60 in 2024, and materially up from the 2014 to 2017 range. That matches the journal's current status as one of the more trusted synthesis venues in aging biology.

The better way to read that trend is not "aging is hot, so the number is high." It is that aging reviews have become more useful as the field has become more mechanistic, more translational, and more crowded. A review that actually clarifies the field now gets cited heavily because the noise level is higher.

The mistake is to assume any well-written review on aging belongs here because the journal is review-only.

That is not the editorial bar. ARR does best when the manuscript does one of four things clearly:

• reorganizes a live mechanistic debate
• sharpens how a disease or intervention should be understood through the aging lens
• separates hype from durable evidence
• gives readers a framework they can actually use in future research

A broad narrative overview can still be publishable somewhere else. It just often is not enough for ARR.

In our pre-submission review work on manuscripts targeting Ageing Research Reviews, the most common failure is not factual weakness. It is editorial softness. The manuscript covers a timely topic, but it never becomes more useful than a careful seminar handout.

Editors at ARR usually want sharper intellectual compression than that. They look for a review that helps readers decide what the field believes, where the evidence is thin, and what should happen next.

In our pre-submission review work on manuscripts targeting Ageing Research Reviews, four failure patterns recur.

The review is descriptive rather than decisional. It summarizes papers but never tells the reader which mechanisms, models, or interventions hold up best.

The topic is too wide for one coherent argument. Aging, senescence, metabolism, immunity, and disease are all relevant, but piling them together rarely produces a review editors can route confidently.

Therapeutic language outruns the evidence. This is common in longevity and intervention reviews. The manuscript starts making translational promises that the cited evidence cannot support cleanly.

The search and selection logic is under-explained. Even a narrative review needs to show enough discipline that editors trust the synthesis was not assembled opportunistically.

If those problems still describe the paper, an Ageing Research Reviews submission readiness check is usually more useful than another round of line editing.